Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00750 (
PLA
)
16,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Group IIa phospholipase A(2) (GIIa
PLA
(2)) is released by some cells in response to interleukin-1beta. The purpose of this study was to determine whether interleukin-1beta would stimulate the synthesis and release of GIIa
PLA
(2) from cardiomyocytes, and to define the role of p38 MAPK and cytosolic
PLA
(2) in the regulation of this process. Whereas GIIa
PLA
(2) mRNA was not identified in untreated cells, exposure to interleukin-1beta resulted in the sustained expression of GIIa
PLA
(2) mRNA. Interleukin-1beta also stimulated a progressive increase in cellular and extracellular GIIa
PLA
(2) protein levels and increased extracellular
PLA
(2) activity 70-fold. In addition, interleukin-1beta stimulated the p38 MAPK-dependent activation of the downstream MAPK-activated protein kinase,
MAPKAP
-K2. Treatment with the p38 MAPK inhibitor, SB202190, decreased interleukin-1beta stimulated
MAPKAP
-K2 activity, GIIa
PLA
(2) mRNA expression, GIIa
PLA
(2) protein synthesis, and the release of extracellular
PLA
(2) activity. Infection with an adenovirus encoding a constitutively active form of MKK6, MKK6(Glu), which selectively phosphorylates p38 MAPK, induced cellular GIIa
PLA
(2) protein synthesis and the release of GIIa
PLA
(2) and increased extracellular
PLA
(2) activity 3-fold. In contrast, infection with an adenovirus encoding a phosphorylation-resistant MKK6, MKK6(A), did not result in GIIa
PLA
(2) protein synthesis or release by unstimulated cardiomyocytes. In addition, infection with an adenovirus encoding MKK6(A) abrogated GIIa
PLA
(2) protein synthesis and release by interleukin-1beta-stimulated cells. These results provide direct evidence that p38 MAPK activation was necessary for interleukin-1beta-induced synthesis and release of GIIa
PLA
(2) by cardiomyocytes.
...
PMID:p38 MAPK regulates group IIa phospholipase A2 expression in interleukin-1beta -stimulated rat neonatal cardiomyocytes. 1157 Dec 75
Apoptosis signal-regulating kinase 1 (ASK1) is a member of mitogen-activated protein kinase kinase kinase (MAP3K) family, which recently has been implicated in the regulation of p38 MAPK/PLA2/thromboxane (TxA
2
) generation, as well as P2Y
12
signalling in murine platelets. ASK1 has therefore been proposed as a potential target for anti-thrombotic therapy. At present it is unknown whether ASK1 also contributes to TxA
2
formation and platelet function in human. In this study we therefore examined the role of ASK1 using the ASK1 inhibitor selonsertib (GS-4997). We established that ASK1 is responsible for p38 phosphorylation and TxA
2
formation in murine platelets, with both GS4997 and p38 inhibitors reducing TxA
2
formation. Similar to murine platelets, activation of human platelets resulted in the rapid and transient phosphorylation of ASK1 and the MAP2Ks MMK3/4/6. In contrast, phosphorylation of p38 and its substrate;
MAPKAP
-kinase2 (MAPKAPK2) was much more sustained. In keeping with these findings, inhibition of ASK1 blocked early, but not later p38/MAPKAPK2 phosphorylation. The latter was dependent on non-canonical autophosphorylation as it was blocked by the p38 inhibitor; SB203580 and the SYK inhibitor; R406. Furthermore, ASK1 and p38 inhibitors had no effect on
PLA
2
phosphorylation, TxA
2
formation and platelet aggregation, demonstrating that this pathway is redundant in human platelets. Together, these results demonstrate that ASK1 contributes to TxA
2
formation in murine, but not human platelets and highlight the importance of confirming findings from genetic murine models in humans.
...
PMID:Redundant role of ASK1-mediated p38MAPK activation in human platelet function. 3191 91